6 news items
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
VIR
11 Apr 24
system by exploiting critical observations of natural immune processes. Its current clinical development pipeline consists of product candidates targeting
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
ANTX
VBIV
VIR
22 Mar 24
of similar import. By their nature, forward looking statements involve risk and uncertainty because they relate to events and depend on circumstances
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
VIR
5 Mar 24
critical observations of natural immune processes. Its current clinical development pipeline consists of product candidates targeting hepatitis delta
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
VIR
23 Feb 24
diseases. Vir has assembled two technology platforms that are designed to modulate the immune system by exploiting critical observations of natural immune
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
VIR
22 Feb 24
.
In December, Nature Medicine recognized the Phase 1 trial of VIR-1388 as one of the "11
ia7uqcfyoxf92anuad6zx4cr2u5eskn7jic7olakx5q9
KYMR
L
LASR
22 Feb 24
) is likely to report quarterly loss at $0.12 per share on revenue of $37.69 million.
• Pioneer Natural Resources
- Prev
- 1
- Next